or
forgot password

    • cancer clinical trials in chester, PA

    • A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients
    Associates in Hematology-Oncology, PC
    Chester, Pennsylvania 19130
    Myelodysplastic Syndrome, MDS, Low to Intermediate-1 MDS, Non-deletion 5q